A phase II trial of sorafenib (SO) in advanced chordoma patients (pt).

Eric Amela,Emmanuelle Bompas,Axel Le Cesne,Emmanuelle Tresch,Antoine Italiano,Sophie Piperno-Neumann,Olivier Collard,Damien Vansteene,Julien Domont,Esma Saada,Nicolas Isambert,Sébastien Salas,Christine Chevreau,François Bertucci,Stephanie Clisant Delaine,Jean-Yves Blay,Nicolas Penel

A phase II trial of sorafenib (SO) in advanced chordoma patients (pt).

2015

Eric Amela
Emmanuelle Bompas
Axel Le Cesne
Emmanuelle Tresch
Antoine Italiano
Sophie Piperno-Neumann
Olivier Collard
Damien Vansteene
Julien Domont
Esma Saada
Nicolas Isambert
Sébastien Salas
Christine Chevreau
François Bertucci
Stephanie Clisant Delaine
Jean-Yves Blay
Nicolas Penel

10520 Background: To report in a hypothesis-generating phase II study the activity and safety of SO in advanced chordomas. Methods: Pts received SO 800 mg/d until progression, intolerance or up to ...

Keywords:

Pathology
Oncology
Sorafenib
Chordoma
Internal medicine
Medicine
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations